eALM1137
eALM1137 is a mTOR inhibitor with an IC50 of 4.8 nM. eALM1137 mediates dual inhibition of the mTORC1 and mTORC2 signaling pathways, and inhibits DNA-PK (IC50=77 nM). eALM1137 exhibits antiproliferative and cytostatic activities, and induces G1 cell cycle arrest. eALM1137 is applicable to the research of glioblastoma multiforme.
For research use only. We do not sell to patients.
- Formula: C22H26N8O3
- Molecular Weight:450.49
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
|
mTORC1 |
mTORC2 |
In Vitro
eALM1137 (0.1-1000 nM; 5 days) potently inhibits U87-MG glioblastoma cell proliferation with an EC50 of 5.1 nM after 5 days of treatment[1].
eALM1137 (0.1-1000 nM; 5 days) potently inhibits T98G glioblastoma cell proliferation with an EC50 of 11 nM after 5 days of treatment[1].
eALM1137 (3 nM, 10 nM, 30 nM, 100 nM, 300 nM) dose-dependently inhibits mTORC1 and mTORC2 signaling in U87-MG and T98G glioblastoma cells, with marked reduction of phosphorylated S6 and Akt at concentrations ≥30 nM[1].
eALM1137 (10-8-10-5 M; 3 days) potently inhibits NPE glioblastoma stem cell proliferation with an EC50 of 85 nM after 3 days of treatment, exerting cytostatic rather than cytotoxic effects[1].
eALM1137 (300 nM; 24 h) inhibits mTORC1 and mTORC2 signaling in NPE glioblastoma stem cells after 24 h of treatment at 300 nM, while inducing compensatory activation of the RAF-MEK-ERK pathway[1].
eALM1137 (0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM; 3 days) induces dose-dependent G1-phase cell cycle arrest in E21 patient-derived glioblastoma stem cells after 3 days of treatment[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:U87-MG glioblastoma multiforme cells
-
Concentration:0.1-1000 nM
-
Incubation Time:5 days
-
Result:Suppressed U87-MG cell proliferation with an EC50 of 5.1 nM.
Showed stronger potency than reference compound sapanisertib (EC50=7.5 nM).
-
Cell Line:E21 patient-derived mesenchymal glioblastoma stem cells expressing FUCCI cell cycle reporter
-
Concentration:0.03 μM, 0.1 μM, 0.3 μM, 1 μM, 3 μM, 10 μM
-
Incubation Time:3 days
-
Result:Induced a strong G1-phase cell cycle arrest in a dose-dependent manner.
Caused significant increases in the percentage of G1-phase cells relative to DMSO control at all tested concentrations.
Chemical Information
-
Molecular Weight 450.49
-
Formula C22H26N8O3
-
SMILES
O=C(N1CCC(CN2N=C(C3=CC=C(OC(N)=N4)C4=C3)C5=C(N)N=CN=C52)CC1)OC(C)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- eALM1137
- eALM 1137
- eALM-1137
- mTOR
- Ribosomal S6 Kinase (RSK)
- Akt
- DNA-PK
- mechanistic target of rapamycin
- U87-MG glioblastoma cell
- glioblastoma multiforme
- mTORC1
- NPE glioblastoma stem cell
- E21 patient-derived glioblastoma stem cell
- mTORC2
- T98G glioblastoma cell
- G1 cell cycle arrest
- RAF-MEK-ERK pathway
- Inhibitor
- inhibitor
- inhibit